Taiwan is mapping out a four-year national pharmaceutical resilience preparedness program that aims to bolster the country’s ...

Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 Earnings Call Transcript March 5, 2026 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07.

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying ...

Thanks, everyone, for being here for TD Cowen's 46th Annual Healthcare Conference. Our next session we have here is with Rocket Pharma. And from Rocket, we have Gaurav Shah, the CEO. Thanks so much ...

Cash and Investments -- $301.8 million as of December 31, 2025, sufficient to fully fund current Phase III HCV and new HEV programs through 2027. Phase III HCV Trials -- C BEYOND enrollment completed ...

KINGSTON, March 5 (Reuters) - Jamaica's foreign ministry on Thursday said the country will end a medical cooperation program with Cuba, according to local media outlet The Gleaner. The two governments ...

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...

Although major pharmaceutical companies have fallen in line with President Donald Trump’s “most favored nation” (MFN) drug pricing agenda, the specifics of their negotiated concessions and the actu | ...

The End the Vaccine Carveout Act would expose vaccine makers to lawsuits that once drove companies out of the industry.

So, on the strength of that trial, Blackman and Grant paid $1 million (plus $10 million in Day One stock) to Takeda and $2 ...

FDA authorized Tec-Dara for RRMM after ≥1 prior line (PI + IMiD exposure), accelerating earlier-line use where attrition and refractoriness erode response with successive regimens. A 55-day review ...